AbbVie (ABBV) has inked a licensing deal with China-based RemeGen for the latter’s RC148, a PD-1/VEGF-targeted bispecific antibody under development for advanced solid tumors.
Given that early studies have indicated initial favorable antitumor activity of RC148 in combination with an antibody-drug conjugate, AbbVie said that it could potentially be used with its own investigational ADC, telisotuzumab adizutecan (Temab-A).
Terms call for AbbVie have exclusive rights to develop, manufacture, and commercialize RC148 outside of the Greater China area. RemeGen will receive an upfront payment of $650M plus potential milestone payments of $4.95B, as well as tiered, double-digit royalties on sales outside of Greater China.
